NEW YORK, Jan. 30, 2017 /PRNewswire/ -- Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington's Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer's. "Vybion is pleased to receive Track I status on INT41 and anticipates rapid review and allowance" said Lee Henderson, Vybion CEO.
INT41 is a new class of drugs called Intrabodies delivered by Gene Therapy for the treatment of Huntington's and similar neurodegenerative diseases. INT41 works by stabilizing the N-terminal "toxic" fragment produced by degradation of the Huntingtin mutant protein, accelerating its degradation, as well as reducing protein aggregation and gene dysregulation, both pivotal in Huntington's disease pathology. Intrabodies may achieve the specificity and safety of monoclonal antibodies (from which Intrabodies are derived), one of the most successful classes of drugs of this century. Delivered by Gene Therapy, Intrabodies may provide opportunities to develop successful therapies against what are considered "hard targets" within the cell.